Patents Examined by Marsha Tsay
  • Patent number: 11319533
    Abstract: The present invention relates to a CRISPR nanocomplex for nonviral genome editing, a method for preparing the same, and the like. The CRISPR nanocomplex for nonviral genome editing of the present invention has a size of several nanometers to several microns, enables intracellular delivery without external physical stimulation, and can be utilized for genome editing through nonviral routes with respect to target genes of cells. As a result, when used for preparation of animal model, microbiological engineering, cell engineering for disease treatment, or formulations for biological administration, the CRISPR Nanocomplex shows high intracellular delivery and gene editing efficiency, and can minimize problems, such as nonspecific editing, gene mutation, and induction of cytotoxicity and biotoxicity.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: May 3, 2022
    Assignee: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Hyun Jung Chung, Yoo Kyung Kang
  • Patent number: 11317623
    Abstract: The technology provided herein relates to novel methods and systems for cell-free protein synthesis, in particular to cell-free protein synthesis systems suitable for protein synthesis before and after freezing for a short- or long-term storage, wherein said system comprises a cryoprotectant.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: May 3, 2022
    Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
    Inventors: Matthias Buntru, Simon Vogel, Stefan Schillberg
  • Patent number: 11319556
    Abstract: The present specification relates to a transformed yeast strain capable of simultaneously utilizing xylose and glucose as carbon sources, a preparation method thereof and a biofuel production method using the same. The transformed yeast strain transforms a wild-type yeast strain incapable of using xylose as a carbon source and simultaneously convert glucose and xylose, thereby enabling high yield production of a biofuel. The economics and sustainability of the biofuel and biomaterial production processes can be highly enhanced by providing a strain which can easily be converted to a strain capable of producing a biofuel/material in a high yield through an additional modification.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: May 3, 2022
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Sun Mi Lee, Phuong Nguyen Hoang Tran, Youngsoon Um, Gyeongtaek Gong, Ja Kyong Ko, Yeonjung Lee
  • Patent number: 11268100
    Abstract: The invention relates to systems, methods, and compositions for the genetic modification of Wolbachia.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: March 8, 2022
    Assignee: Vanderbilt University
    Inventors: Sarah R. Bordenstein, Seth R. Bordenstein
  • Patent number: 11260109
    Abstract: The present invention relates to a product and method of using albumin nanoparticles for augmenting the function or effectiveness of stem cells or precursor cells in vivo. An albumin nanoparticle suspension containing submicron albumin spheres is prepared, with the albumin spheres being capable of augmenting a function and effectiveness of stem cells or precursor cells in vivo. A predetermined amount of the albumin nanoparticle suspension is administered to a patient before or after an onset of at least one condition. The condition is one that can benefit from a healing effect of the stem cells or precursor cells. A function of the stem cells or precursor cells are augmented or improved by the albumin spheres to repair cellular or tissue damage, resulting in decreasing mortality or morbidity of the patient. The albumin spheres can be bound with fibrinogen molecules in vitro or in vivo.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: March 1, 2022
    Inventor: Richard C. K. Yen
  • Patent number: 11260110
    Abstract: A method of treating radiation-induced skin toxicity or skin ulcers with nanoparticles after exposure to ionizing radiation and after an onset of radiation-induced skin toxicity or a radiation-induced skin ulcer by administering intravenously a suspension including fibrinogen-coated albumin nanospheres to a patient. A concentration of the suspension being sufficient to at least one of promote healing of the skin toxicity or reduce a size of the skin ulcer. The suspension can include fibrinogen-coated albumin nanospheres, sorbitol and/or caprylate. The suspension can be utilized for treating a patient to reduce an amount of blood loss in an organ of the patient or for treating a patient to mobilize stem cells or progenitor cells to accelerate healing of a wound.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: March 1, 2022
    Assignee: PTLNV, LLC, series four (4)
    Inventor: Richard C. K. Yen
  • Patent number: 11261437
    Abstract: The present disclosure provides protease-activatable procoagulant compounds comprising a procoagulant polypeptide, e.g., a procoagulant peptide and/or clotting factor, and a linker comprising a protease-cleavable substrate (e.g., a synthetic thrombin substrate) and a self-immolative spacer (e.g., p-amino benzyl carbamate). Upon cleavage of the protease-cleavable substrate by a protease (e.g., thrombin), the self-immolative spacer cleaves itself from the procoagulant polypeptide such that the polypeptide is in an underivatized and active form. Also provided are pharmaceutical compositions, methods for treating bleeding disorders using the disclosed compounds, methods of enhancing in vivo efficacy of procoagulant polypeptides, methods of increasing the efficacy of proteolytic cleavage of compounds comprising procoagulant polypeptides, methods of activating procoagulant polypeptides, and methods of releasing a procoagulant polypeptide from a heterologous moiety such as PEG.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: March 1, 2022
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Vu Phong Hong, Adam R. Mezo, Joe Salas, Robert Peters
  • Patent number: 11236328
    Abstract: It is disclosed a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, mammalian euglobulin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide. Liquid defibrotide formulations are also disclosed, preferably water solutions, having a defined biological activity and, in particular, having an activity of 25 to 35 IU/mg of defibrotide, preferably from 27 to 32 IU/mg and, more preferably, from 28 to 32 IU/mg.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: February 1, 2022
    Assignee: GENTIUM S.R.L.
    Inventors: Terenzio Ignoni, Vijay Kumar, Khalid Islam
  • Patent number: 11224218
    Abstract: The present invention relates to isolated haemoglobin from worms belonging to the Nereididae family and its use in cell culture medium, in preservation solutions and as artificial oxygen carrier for transfusion.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: January 18, 2022
    Assignee: HEMARINA
    Inventors: Morgane Rousselot, Delphine Dutheil, Franck Zal
  • Patent number: 11203747
    Abstract: The present invention relates to methods for purifying or enriching a biomolecule using multimodal resins and an elution buffer containing a Good's buffer.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: December 21, 2021
    Assignee: Genzyme Corporation
    Inventors: Rahul Godawat, Daniel Cummings, Veena Warikoo
  • Patent number: 11203749
    Abstract: Nucleic acids encoding modified factor VII polypeptides, vectors and cells containing the nucleic acids, uses of the nucleic acids, methods of making the encoded polypeptides, and methods of treatment are provided. The encoded modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among the encoded modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: December 21, 2021
    Assignee: CATALYST BIOSCIENCES, INC.
    Inventors: Edwin L. Madison, Christopher Thanos
  • Patent number: 11191837
    Abstract: The present invention provides long-term stable pharmaceutical formulations of recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: December 7, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Peter Matthiessen, Peter Turecek, Hans-Peter Schwarz, Kurt Schnecker
  • Patent number: 11185573
    Abstract: Disclosed are compositions and methods related to Factor VIII.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: November 30, 2021
    Assignee: Haplomics, Inc.
    Inventor: Thomas E. Howard
  • Patent number: 11168316
    Abstract: The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation. The enhancer moiety can additionally improve procoagulation activities of the chimeric clotting factors. The chimeric clotting factors can further be improved by fusion to a half-life extender, which improves a pharmacokinetics property of the chimeric clotting factor. The invention also includes methods of making and methods of using these chimeric clotting factors.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: November 9, 2021
    Assignee: Bioverativ Therapeutics, Inc.
    Inventors: Joe Salas, Elena Kistanova, Vu Phong Hong, Adam R. Mezo, Robert T. Peters
  • Patent number: 11160474
    Abstract: Provided herein is a stabilized oxygen transport matrix that includes a reversible oxygen binding protein, such as hemoglobin, immobilized throughout the stabilized oxygen transport matrix. The stabilized oxygen transport matrix is used to transport oxygen and can be used as an oxygen transport region and a reaction region of an analyte sensor, such as an implantable glucose sensor. The reversible binding protein can also function as an oxygen probe within the analyte sensor.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: November 2, 2021
    Assignee: Metronom Health, Inc.
    Inventors: Elliot Botvinick, Troy M. Bremer
  • Patent number: 11124788
    Abstract: The present invention is directed to enzymes having Asx-specific ligase and cyclase activity and to nucleic acids encoding those as well as methods of the manufacture of said enzymes. Further encompassed are methods and uses of these enzymes.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: September 21, 2021
    Assignee: NANYANG TECHNOLOGICAL UNIVERSITY
    Inventors: Kien Truc Giang Nguyen, James P. Tam
  • Patent number: 11085043
    Abstract: It is disclosed a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, mammalian euglobulin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide. Liquid defibrotide formulations are also disclosed, preferably water solutions, having a defined biological activity and, in particular, having an activity of 25 to 35 IU/mg of defibrotide, preferably from 27 to 32 IU/mg and, more preferably, from 28 to 32 IU/mg.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: August 10, 2021
    Assignee: GENTIUM S.R.L.
    Inventors: Terenzio Ignoni, Vijay Kumar, Khalid Islam
  • Patent number: 11046749
    Abstract: A chimera protein according to the present application has a significantly increased in vivo half-life when administered because of a vWF domain coupled to FVIII, such that when used as a hemophilia A therapeutic agent, convenience for patients can be increased and medical expenses can be reduced.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: June 29, 2021
    Assignee: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Injae Oh, Seung-Hoon Lee, Eui-Cheol Jo, Mee Sook Oh, Jae Hwan Ryu, Yong Jae Kim, So Ra Kim, Jin-hyun Park
  • Patent number: 11020100
    Abstract: Provided herein are systems for preparing and delivering fibrin sealant to a surface and methods of use thereof. In one embodiment, the system comprises: a. a quantity of a liquid mixture disposed within a container, the mixture comprising: I. fibrin or II. fibrinogen and Factor II; and b. a resin bed disposed within a vessel, the vessel capable of being in fluid communication with the container, wherein when in fluid communication, passage of the mixture through the vessel results in modification of the concentration of small molecules inhibitor(s) and/or inducer(s) within the mixture, favoring fibrin clot formation.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: June 1, 2021
    Assignees: Omrix Biopharmaceuticals, Ltd., Ethicon, Inc.
    Inventors: Ashley DeAnglis, Yair Pilpel, Yuri Zherdev, Sivan Doron, Lior Erez
  • Patent number: 11020459
    Abstract: A Factor VIII (FVIII) composition formulated such that NaCl is not present in the final formulation or is present in trace amounts, which allows for a concomitant reduction in the lyophilization cycle time and increased stability of the lyophilized FVIII.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: June 1, 2021
    Assignees: Baxalta Incorporated, Baxalta GmbH, University of Connecticut
    Inventors: Michael Pikal, Serguei Tchessalov, Erik Bjornson, Feroz Jameel, Marc Besman